CA
NZ
UK
AU
IND
US
…
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Absci Corp operates a platform combining computational methods and biological engineering to discover and optimize therapeutic proteins, and offers discovery services through partner collaborations. Long-term growth may be driven by wider adoption of engineered biologics, additional licensing and collaboration deals, and platform scalability, which could appeal to investors seeking technology-enabled exposure to biologics discovery.
Material risks include high R&D spending with limited commercial revenue, reliance on a small number of collaboration agreements, scientific or regulatory failure of programs, and likely equity dilution to finance operations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -115.11M | -103.04M | -110.47M | -105.36M | -109.86M |
| Net income | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M |
| Selling general administrative | 35.06M | 36.17M | 36.26M | 40.55M | 28.78M |
| Gross profit | -8.94M | -57.92M | -41.85M | 5.75M | 4.78M |
| Reconciled depreciation | 11.74M | 13.39M | 14.10M | 13.04M | 6.65M |
| Ebit | -124.72M | -107.49M | -93.68M | -106.75M | -75.24M |
| Ebitda | -112.98M | -94.10M | -79.68M | -91.36M | -99.77M |
| Depreciation and amortization | 11.74M | 13.39M | 14.00M | 15.39M | -24.54M |
| Non operating income net other | - | - | - | - | -31.19M |
| Operating income | -124.72M | -108.89M | -115.52M | -106.75M | -75.24M |
| Other operating expenses | 127.52M | 113.42M | 121.23M | 112.50M | 80.02M |
| Interest expense | 0.21M | 0.56M | 1.01M | 0.97M | 3.43M |
| Tax provision | 0.07M | 0.07M | -0.45M | -0.46M | -8.90M |
| Net interest income | -0.21M | -0.56M | -1.09M | -0.97M | -3.43M |
| Income tax expense | 0.07M | 0.07M | 0.10M | -0.46M | -8.90M |
| Total revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M |
| Total operating expenses | 115.78M | 50.96M | 73.67M | 112.50M | 80.02M |
| Cost of revenue | 11.74M | 62.46M | 47.57M | - | 6.65M |
| Total other income expense net | 9.60M | 5.85M | 5.05M | 1.39M | -34.62M |
| Net income from continuing ops | -115.18M | -103.11M | -106.49M | -104.90M | -100.96M |
| Net income applicable to common shares | - | - | - | -104.90M | -103.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 216.30M | 213.61M | 234.48M | 321.01M | 426.19M |
| Intangible assets | 41.51M | 44.88M | 48.25M | 51.62M | 54.99M |
| Other current assets | 5.28M | 21.41M | 4.54M | 5.86M | 8.57M |
| Total liab | 26.85M | 34.48M | 58.30M | 46.59M | 60.09M |
| Total stockholder equity | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M |
| Deferred long term liab | - | - | - | - | 0.74M |
| Other current liab | 16.59M | 19.59M | 19.30M | 20.48M | 17.43M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -624.78M | -509.60M | -406.50M | -295.93M | -191.03M |
| Other liab | - | - | - | 0.27M | 12.90M |
| Good will | - | - | 0.00M | 21.34M | 21.34M |
| Other assets | - | - | 0.00M | 3.15M | 18.14M |
| Cash | 20.02M | 41.21M | 88.56M | 59.95M | 252.57M |
| Total current liabilities | 22.77M | 28.66M | 29.56M | 30.27M | 33.86M |
| Current deferred revenue | 0.74M | 1.12M | 3.17M | 0.45M | 1.35M |
| Net debt | -14.72M | -31.11M | -72.60M | -36.97M | -232.56M |
| Short term debt | 2.68M | 4.42M | 5.58M | 6.93M | 6.69M |
| Short long term debt | 0.87M | 2.73M | 3.26M | 2.95M | 2.40M |
| Short long term debt total | 5.30M | 10.11M | 15.96M | 22.98M | 20.01M |
| Other stockholder equity | 813.63M | 688.73M | 582.70M | 570.45M | 130.94M |
| Property plant equipment | - | - | - | 58.04M | 58.65M |
| Total current assets | 149.57M | 133.83M | 120.58M | 186.86M | 273.08M |
| Net tangible assets | - | - | - | 201.46M | 289.78M |
| Short term investments | 124.27M | 71.21M | 25.30M | 104.48M | - |
| Net receivables | - | 0.00M | 2.19M | 1.55M | 1.43M |
| Long term debt | - | 1.26M | 4.66M | 7.98M | 1.12M |
| Inventory | - | - | - | 15.02M | 10.51M |
| Accounts payable | 2.76M | 3.53M | 1.50M | 2.41M | 8.38M |
| Accumulated other comprehensive income | 0.59M | -0.00M | -0.04M | -0.12M | -0.01M |
| Common stock total equity | - | - | - | - | 0.01M |
| Retained earnings total equity | - | - | - | - | -191.03M |
| Non currrent assets other | 1.44M | 1.76M | 1.54M | 3.15M | 18.14M |
| Non current assets total | 66.72M | 79.78M | 113.90M | 134.15M | 153.12M |
| Capital lease obligations | 4.43M | 6.12M | 8.04M | 12.05M | 16.49M |
| Long term debt total | - | - | - | - | 1.12M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -50.37M | -41.58M | 32.81M | -126.98M | -1.20M |
| Change to liabilities | - | - | - | -1.44M | 2.15M |
| Total cashflows from investing activities | -50.16M | -41.58M | 81.94M | -126.98M | -67.38M |
| Net borrowings | -3.20M | -4.03M | -5.34M | 4.58M | 123.40M |
| Total cash from financing activities | 105.95M | 82.53M | -4.48M | 5.24M | 336.19M |
| Change to operating activities | - | - | - | 0.05M | -3.67M |
| Net income | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M |
| Change in cash | -37.14M | -31.45M | 12.82M | -203.08M | 208.22M |
| Begin period cash flow | 58.21M | 89.67M | 76.84M | 279.93M | 71.71M |
| End period cash flow | 21.08M | 58.21M | 89.67M | 76.84M | 279.93M |
| Total cash from operating activities | -92.92M | -72.40M | -64.64M | -81.34M | -60.60M |
| Issuance of capital stock | 105.83M | 86.56M | 0.79M | 0.66M | 215.34M |
| Depreciation | 11.74M | 13.39M | 14.00M | 13.04M | 6.65M |
| Other cashflows from investing activities | - | 0.94M | 0.25M | 0.65M | -29.33M |
| Change to account receivables | 0.00M | 2.24M | -0.67M | -0.15M | 0.23M |
| Sale purchase of stock | - | - | - | - | 210.40M |
| Other cashflows from financing activities | - | - | 81.94M | 12.03M | 129.94M |
| Change to netincome | - | - | - | 12.07M | 2.01M |
| Capital expenditures | 1.11M | 0.40M | 0.86M | 16.18M | 38.05M |
| Cash flows other operating | - | - | - | - | 29.55M |
| Cash and cash equivalents changes | - | - | - | - | 208.22M |
| Change in working capital | 0.42M | -0.37M | 1.52M | -1.54M | -3.15M |
| Stock based compensation | 18.32M | 19.45M | 11.42M | 12.54M | 10.61M |
| Other non cash items | -8.23M | -1.77M | 19.05M | 0.03M | 35.15M |
| Free cash flow | -94.03M | -72.81M | -65.50M | -97.51M | -98.64M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABSI Absci Corp |
0.42 4.33% |
10.11 | - | - | 872.91 | 5.64 | 763.00 | -0.39 |
| NVO Novo Nordisk A/S |
-0.11 0.27% |
40.34 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-16.25 2.94% |
536.90 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.79 1.02% |
971.05 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683
360 949 1041
140
| Name | Title | Year Born |
|---|---|---|
| Mr. Sean McClain | Founder, CEO, Pres & Director | 1991 |
| Dr. Sarah Korman J.D., Ph.D. | Chief Legal Officer & Corp. Sec. | 1979 |
| Mr. Gregory T. Schiffman CPA, CPA, MBA | Chief Financial Officer | 1957 |
| Todd Bedrick CPA | Sr. VP & Chief Accounting Officer | NA |
| Mr. Jack Gold | Chief Marketing Officer | NA |
| Melissa Patterson Ph.D. | Chief of Staff | NA |
| Ms. Denise Dettore | Chief People Officer | NA |
| Dr. Andreas Busch Ph.D. | Chief Innovation Officer | 1963 |
| Jonathan Eads M.S. | Sr. VP of Informatics | NA |
| Thomas Wrona J.D., Ph.D. | Sr. VP of Intellectual Property | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.10%
Communication Services
+0.51%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.44%
Energy
-0.15%
Financial Services
-0.03%
Financials
+0.43%
Healthcare
+0.73%
Industrials
+0.57%
Real Estate
-0.32%
Technology
+1.29%
Utilities
+0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...